Journal of Cancer Research and Therapeutics Close
 

Figure 3: Progression-free survival according to tumor shrinkage rate in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutations after first-line tyrosine kinase inhibitor therapy. The survival rates were calculated using the Kaplan–Meier method, and statistical significance was compared using log-rank tests (P < 0.001)

Figure 3: Progression-free survival according to tumor shrinkage rate in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutations after first-line tyrosine kinase inhibitor therapy. The survival rates were calculated using the Kaplan–Meier method, and statistical significance was compared using log-rank tests (<i>P</i> < 0.001)